We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+9.25%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$398M
AUM Growth
+$20.8M
Cap. Flow
+$11.1M
Cap. Flow %
2.8%
Top 10 Hldgs %
51.36%
Holding
92
New
12
Increased
23
Reduced
18
Closed
5

Top Buys

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$4.8M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$3.99M
3
AXGN icon
Axogen
AXGN
+$3.98M
4
ACET icon
Adicet Bio
ACET
+$3.83M
5
BMEA icon
Biomea Fusion
BMEA
+$3.32M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$11.8M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$3.81M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$2.74M
4
AFMD
Affimed
AFMD
+$2.43M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$1.83M

Sector Composition

Rank Sector Weight
1 Healthcare 94.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BWAY
51
Brainsway
BWAY
$627M
$1.54M 0.39%
400,000
– –
SURF
52
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$1.51M 0.38%
+315,000
New +$2.03M
ASND icon
53
Ascendis Pharma A/S
ASND
$16.3B
$1.48M 0.37%
+11,000
New +$1.64M
MGNX icon
54
MacroGenics
MGNX
$252M
$1.45M 0.36%
90,000
– –
NGM
55
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$1.43M 0.36%
80,485
+15,000
+23% +$288K
STIM icon
56
Neuronetics
STIM
$159M
$1.4M 0.35%
313,717
– –
RDUS
57
DELISTED
Radius Health, Inc.
RDUS
$1.33M 0.33%
191,978
+177,478
+1,224% +$2.6M
THRX
58
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$1.24M 0.31%
+97,500
New +$1.47M
WVE icon
59
Wave Life Sciences
WVE
$1.18B
$1.23M 0.31%
+390,161
New +$1.62M
NXTC icon
60
NextCure
NXTC
$21.2M
$1.13M 0.28%
15,641
+350
+2% +$29.3K
BDTX icon
61
Black Diamond Therapeutics
BDTX
$108M
$1.1M 0.28%
+206,100
New +$1.44M
PHAS
62
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$988K 0.25%
378,611
-224,431
-37% -$678K
MASI
63
DELISTED
Masimo
MASI
$878K 0.22%
3,000
– –
MRSN
64
DELISTED
Mersana Therapeutics
MRSN
$872K 0.22%
5,611
– –
CGEN icon
65
Compugen
CGEN
$218M
$866K 0.22%
201,502
– –
REUN
66
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$839K 0.21%
68,180
– –
ASLN
67
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$820K 0.21%
18,313
– –
HARP
68
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$794K 0.2%
10,516
– –
LVTX
69
DELISTED
LAVA Therapeutics
LVTX
$766K 0.19%
139,332
– –
LRMR icon
70
Larimar Therapeutics
LRMR
$434M
$757K 0.19%
70,177
+5,690
+9% +$63.3K
HOOK
71
DELISTED
HOOKIPA Pharma
HOOK
$747K 0.19%
32,044
-168
-0.5% -$6.75K
SCYX icon
72
SCYNEXIS
SCYX
$51.4M
$740K 0.19%
+15,155
New +$745K
PRQR icon
73
ProQR Therapeutics
PRQR
$272M
$685K 0.17%
85,476
-210,907
-71% -$1.61M
STRO icon
74
Sutro Biopharma
STRO
$398M
$670K 0.17%
4,500
-4,000
-47% -$717K
CMPX icon
75
Compass Therapeutics
CMPX
$348M
$622K 0.16%
+196,091
New +$650K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, DAFNA Capital Management held 92 positions worth $398M, up 5.5% from $377M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DAFNA Capital Management's Q4 2021 filing shows 12 new, 23 increased, 18 reduced and 5 closed positions. Its largest new stake was Axogen: 332,103 shares worth $3.11M. The largest sale was Dicerna Pharmaceuticals, Inc., an estimated $11.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier.

  • DAFNA Capital Management's largest Q4 2021 buy was Axogen: 332,103 shares worth $3.11M.
  • DAFNA Capital Management added most to Cymabay Therapeutics in Q4 2021, an estimated $4.8M increase.
  • DAFNA Capital Management's biggest Q4 2021 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $3.81M.
  • DAFNA Capital Management fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $11.8M.
  • DAFNA Capital Management's ten largest holdings make up 51% of its $398M portfolio in Q4 2021.
  • DAFNA Capital Management opened 12 new positions and closed 5 in Q4 2021.
  • DAFNA Capital Management's portfolio value rose 5.5% quarter-over-quarter to $398M.

Based on DAFNA Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.